Tenofovir CAS: 147127-20-6
MF: C9H14N5O4P
MW: 287.21
A selective HIV reverse transcriptase (HIV-1 RT) inhibitor.

Tenofovir (CAS 147127-20-6)

Tenofovir | CAS 147127-20-6 is rated 5.0 out of 5 by 1.
  • y_2020, m_9, d_18, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204335, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 126ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Viread; PMPA; (R)-9-(2-Phosphonoylmethoxypropyl)adenine
Application: Tenofovir is a selective HIV reverse transcriptase (HIV-1 RT) inhibitor
CAS Number: 147127-20-6
Purity: ≥98%
Molecular Weight: 287.21
Molecular Formula: C9H14N5O4P
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

Tenofovir is a selective antiretroviral agent which functions as a HIV reverse transcriptase inhibitor. Studies indicate that Tenofovir shows a low cytotoxicity in human cell types compared to other nucleoside reverse transcriptase inhibitors. It is known that HIV replicates its double stranded DNA via reverse transcriptase and then the DNA is integrated into the hosts chromosomes. Tenofovir functions by inhibiting the replication of this DNA. Furthermore, studies suggest that Tenofovir prevents cytoxicity in SIV-infected C-8166 cells in vitro.


References

1. Tsai, C.C., et al. 1995. Science. 270: 1197-1199. PMID: 7502044
2. Van Rompay, K.K., et al. 1996. Antimicrob. Agents Chemother. 40: 2586-2591. PMID: 8913470
3. Cihlar, T., et al. 2002. Antiviral Res. 54: 37-45. PMID: 11888656

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO (10 mM), 1.1 eq.NaOH (100 mM), water (2 mg/ml at 25° C), and ethanol (<1 mg/ml at 25° C).
Storage :
Store at -20° C
Melting Point :
480.00° C (Predicted)
Boiling Point :
~616.1° C at 760 mmHg
Density :
~1.8 g/cm3 (Predicted)
Refractive Index :
n20D 1.74 (Predicted)
IC50 :
Hepatitis B virus: IC50 = 0.54 µM; Human immunodeficiency virus 1: IC50 = 0.82 µM; Hepatitis B virus: IC50 = 0.89 µM; Cytotoxicity in SIV-infected C-8166 cells: IC50 = 1.5 µM; Vaccinia virus: IC50 = 300 µM
pK Values :
pKa: 1.61 (Predicted), pKb: 4.22 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
SZ6563600
PubChem CID :
464205
MDL Number :
MFCD00943794
SMILES :
C[[email protected]](CN1C=NC2=C1N=CN=C2N)OCP(=O)(O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Tenofovir (CAS 147127-20-6)  Product Citations

See how others have used Tenofovir (CAS 147127-20-6). Click on the entry to view the PubMed entry .

Citations 1 to 9 of 9 total

PMID: # 30039346  Suter-Dick, L. et al. 2018. AAPS J. 20: 86.

PMID: # 27249967  Costa, S. et al. 2016. Parasitology research.

PMID: # 26779022  Mandíková, J. et al. 2015. Frontiers in pharmacology. 6: 304.

PMID: # 24906916  Chen, Z. et al. 2014. American journal of physiology. Heart and circulatory physiology. 307: H328-36.

PMID: # 24957831  2014. Antimicrobial agents and chemotherapy. 58: 5650-7.

PMID: # 24487230  Thein, P. et al. 2014. Hear. Res. 310: 27-35.

PMID: # 22499243  Gokulgandhi, MR. et al. 2012. Journal of pharmaceutical sciences. 101: 3249-63.

PMID: # 15280794  Edelstein, HE. et al. 2004. AIDS. 18: 1748-1749.

PMID: # 15280790  Saumoy, M. et al. 2004. AIDS. 18: 1741-1742.

Citations 1 to 9 of 9 total

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. The chemical, sc-204335, is provided as a white to off-white powder. If you have any further questions or concerns, please feel free to contact our Technical Service department by calling 800-457-3801 option 2, emailing [email protected], or using the Live Chat function on our website.
Answered by: Tech Service 8
Date published: 2017-01-12
  • y_2020, m_9, d_18, h_17CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_204335, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 152ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Rollenhage Rollenhage, C. et al. (PubMed 26121689) combined Tenofovir (Viread), a selective antiretroviral agent which functions as a HIV reverse transcriptase inhibitor, with polyinosinic:polycytidylic in HIV infected tissue. They found that this combination demonstrated an earlier and greater decrease in HIV replication compared to tenofovir only treated tissue. -SCBT Publication Review
Date published: 2015-04-08
  • y_2020, m_9, d_18, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_204335, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 14ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.